Dr Lal Pathlabs Ltd Share Price – NSE  / BSE

Healthcare, Small Cap

Dr Lal Pathlabs has allotted 93,900 equity shares under Dr. Lal PathLabs Employee Stock Option Plan, 2022.

Pursuant to the above allotment, the paid-up equity share capital of the Company increased to Rs 83,57,42,520/- divided into 8,35,74,252 equity shares of Rs 10/- each.

Powered by Capital Market - Live News

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 7 August 2024, inter alia, have recommended the interim dividend of Rs 6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Net profit of Dr Lal Pathlabs rose 28.81% to Rs 106.40 crore in the quarter ended June 2024 as against Rs 82.60 crore during the previous quarter ended June 2023. Sales rose 11.26% to Rs 601.90 crore in the quarter ended June 2024 as against Rs 541.00 crore during the previous quarter ended June 2023.

Powered by Capital Market - Live News

Revenue from operations increased 11.26% YoY to Rs 601.9 crore during the quarter.

Profit before tax (PBT) stood at Rs 149.9 crore, up 27.57% as comapred with Rs 117.5 crore posted in same quarter last year.

Total expenses increased 7.92% to Rs 472.6 crore in Q1 FY25 as compared with Rs 437.9 crore posted in corresponding quarter last year. Cost of material consumed stood at Rs 119.4 crore (up 5.57% YoY), employee benefit expenses was at Rs 116.6 crore (up 11.37% YoY), fees to collection centers/ channel partners was at Rs 83.7 crore (up 12.35% YoY) during the period under review.

During the quarter EBITDA jumped to Rs 170 crore as compared with Rs 146 crore posted in same quarter last year, registering the growth of 16.2%.

Meanwhile, the company’s board declared interim dividend of Rs 6 per share for FY25.

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. As on 31 March 2023, the company has 277 clinical laboratories, 5,102 patient service centers (PSCs) and 10,938 pick-up points (PUPs).

Powered by Capital Market - Live News